Passa al contenuto
Merck

Vai a

1224981

USP

Donepezil hydrochloride

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(±)-2-[(1-Benzyl-4-piperidyl)methyl]-5,6-dimethoxy-1-indanone hydrochloride, 2,3-Dihydro-5,6-dimethoxy-2-{[1-(phenylmethyl)-4-piperidinyl]methyl}-1H-inden-1-one

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
200 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
1.820,00 €

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C24H29NO3 · HCl
Numero CAS:
Peso molecolare:
415.95
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

1.820,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


grade

pharmaceutical primary standard

agency

USP

API family

donepezil

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.N2(CCC(CC2)CC3Cc4c(cc(c(c4)OC)OC)C3=O)Cc1ccccc1

InChI

1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H

InChI key

XWAIAVWHZJNZQQ-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
Y0002160D6821PHR1584
USP

USP

1224981

Donepezil hydrochloride

Donepezil hydrochloride CRS, European Pharmacopoeia (EP) Reference Standard

Y0002160

Donepezil hydrochloride

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

-

grade

pharmaceutical primary standard

grade

-

grade

-

grade

certified reference material, pharmaceutical secondary standard

format

neat

format

-

format

-

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

-

application(s)

pharmaceutical (small molecule)

API family

donepezil

API family

donepezil

API family

-

API family

donepezil


Still not finding the right product?

Explore all of our products under Donepezil hydrochloride


pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2

Classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Manabu Ikeda et al.
Dementia and geriatric cognitive disorders, 36(3-4), 229-241 (2013-08-21)
To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized
Yusuke Yatabe et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 13(2), 88-93 (2013-08-06)
With the recent approval of several new drugs, pharmacological management of Alzheimer's disease has become more complicated in Japan. The efficacy and safety of increasing the dose of donepezil to 10 mg daily were assessed in an open-label study of patients
Marwan Sabbagh et al.
BMC geriatrics, 13, 56-56 (2013-06-08)
Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated



Numero articolo commerciale globale

SKUGTIN
1224981-200MG04061838721303

Domande

Recensioni

Nessuna valutazione

Filtri attivi